Dr. Evelyn Walter

Tel: +43-1-513 20 07-13

Education and Career

Evelyn Walter was born in 1968 in Klagenfurt. She studied economics at the Vienna University of Economics and Business Administration and received her doctorate in economics. She was a research assistant at the Institute of Industrial Sciences (IWI) and later head of the competence area of health economics. In 2003 she was co-founder and managing director of the Institute for Pharmaeconomic Research (IPF) (since 2015 IPF GmbH). She established "Health Economic Evaluation" as the scientific field of health economics in Austria. Evelyn Walter was the initiator of the "Guidelines for Health Economic Evaluation" in Austria. She is a member of the scientific advisory board "System of Health Accounts". At the University of Applied Sciences Pinkafeld she teaches health economic evaluation, health technology assessment and pharmaceutical management as well as scientific methods. 

Evelyn Walter was Co-Chair of Research Review Committees at 17th und 18th Annual European ISPOR Congress.

Evelyn Walter is editor and co-author of the book "Regulatory and Economic Aspects in Oncology" in the publication series Recent Results in Cancer Research, vol 213 Springer Verlag 2019.

Selected Publications

Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective. Walter E, Dawoud C, Hütterer E, Stift A, Harpain F. The American journal of clinical nutrition. 2024 May;119(5):1187-1199. doi: 10.1016/j.ajcnut.2024.02.031. Epub 2024 Mar 1.

The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria. Walter E, Traunfellner M, Gleitsmann M, Zalesak M, Helmenstein C. J Med Econ. 2023 Jan-Dec;26(1):1432-1444. doi: 10.1080/13696998.2023.2264718.

Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland. Walter E, Arrigo M, Allerstorfer S, Marty P, Hülsmann M. J Med Econ. 2023 Jan-Dec;26(1):1287-1300. doi: 10.1080/13696998.2023.2264722.

Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria. Walter E, Eichhober G, Voit M, Baumgartner C, Celedin A, Holzhauser C, Mraz B, Ornauer C, Pleiner-Duxneuner J, Ponner B, Presch I, Pum G, Tieben H, Weingartmann G, Baltic D, Bonitz W, Kaehler ST. J Med Econ. 2020

Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System. Walter E, Heringlake M. J Cardiothorac Vasc Anesth. 2019 Nov 9. pii: S1053-0770(19)31140-1. doi: 10.1053/j.jvca.2019.11.003.

Approaches to Capturing Value in Oncology. Walter E. Recent Results Cancer Res. 2019;213:85-108. doi: 10.1007/978-3-030-01207-6_7.

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. Walter E, Berger T, Bajer-Kornek B, Deisenhammer F. J Med Econ. 2019 Mar;22(3):226-237. doi: 10.1080/13696998.2018.1556668. Epub 2018 Dec 21.

Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. Walter E, Dellago H, Grillari J, Dimai HP, Hackl M. Bone. 2018 Mar;108:44-54. doi: 10.1016/j.bone.2017.12.017. Epub 2017 Dec 18.

Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. PLoS Negl Trop Dis. 2017 Jul 10;11(7):e0005648. doi: 10.1371/journal.pntd.0005648. eCollection 2017 Jul.

Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany. E. Walter, P. Odin. J Med Econ. 2015; 18(11): 860-862

Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany. E. Walter, P. Odin. J Med Econ. 2015 Feb;18(2):155-65

Socio-economic aspects of the testing for antibodies in MS-Patients under Interferon Therapy in Austria: A cost of Illness Study. Water E, Deisenhammer F. Mult Scler Relat Disord. 2014 Nov;3(6):670-7

Kosteneffektivität der primärprofilatischen Gabe von Pegfilgrastim vs. Filgrastim bei Brustkrebspatienten in Österreich. Walter E. In: Recht der Medizin Beilage Gesundheit und Ökonomie, Dezember 2013

Cost Efectividad del Tratamiento de la Anemia inducida por quimioteerapia con agentes estimuladores dela Eritropoyesis. César A. Rodríguez, Adrián Alegre, Javier Cassinello, Laura Gutiérrez, Carlos Crespo, Alba Villacampa, Evelyn Walter. in; PharmaEconomics Spanish Resarch Articles, August 2013 

Pharmaökonomische Aspekte von Biosimilars : Kosteneffektivitätsvorteil? E. Walter. In: Pharmazie in unserer Zeit; Volume 41, Issue 6, pages 485–491, November 2012

Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries. Duran A, Spaepen E, Lamotte M, Walter E, Umuhire D, Lucioni C, Pinheiro B, Brosa M, Kutikova L, Pujol B, Van Belle S, Annemans L. in: J Med Econ. 2012;15(3):409-18.

Access to pharmaceutical products in six European countries – analysis of different pharmaceutical distribution systems. E. Walter, A. Dragosits, M. Said in: Farmaeconomia. Health economics and therapeutic pathways 2012; 13(1): 33-41

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria. B. Resch, C. Sommer, M.J.C. Nuijten, S. Seidinger, E. Walter, V. Schöllbauer, W.D. Mueller. In: The Pediatric Infectious Disease Journal 2012; 31

Cost analysis of neonatal and pediatric parenteral nutrition in Europe – a multi-country study. E. Walter, F.X. Liu, P. Maton, T. Storme, M. Perrinet, O. von Delft, J. Puntis, D. Hartigan, A. Dragosits, S. Sondhi. In: European Journal of Clinical Nutrition 2012

How to save money: congenital CMV infection and the economy. E Walter, C. Brennig, V. Schöllbauer. Buchbeitrag in: Congenital Cytomegalovirus Infection Epidemiology, Diagnosis, Therapy Halwachs-Baumann, Gabriele (Ed.) 2011

Impact of stereotactic 11-g vacuum-assisted breast biopsy on cost of diagnosis in Austria. R. Gruber, E. Walter, Th. Helbich. In: European Journal of Radiology, October 2009

Cost comparison between ultrasound-guided 14-g large core breast biopsy and open surgical biopsy: An analysis for Austria. R. Gruber, E. Walter, Th. Helbich). In: European Journal of Radiology, March 2009

Medikamentenkosten im Bereich Onkologie im Gesundheitsökonomischen Kontext. E. Walter, A Batista. In: Wiener Medizinische Wochenschrift April 2008

Kosteneffektive Prävention von Chemotherapie-induzierter Übelkeit und Erbrechen (CINV) in der supportiven Behandlung von Krebspatienten. E. Walter, S. Zehetmayr. In: Recht der Medizin, Beilage Ö&G, Heft 03 / 2007

Kosteneffektivität von Solifenacin bei der Behandlung der überaktiven Blase in Österreich. E. Walter, C Brennig. In: Recht der Medizin, Beilage Ö&G, Heft 03 / 2007 

Kosteneffektivität von Rosuvastatin versus Simvastatin: 1st Line Behandlung in Österreich. S. Zehetmayr, E. Walter. In: Krause & Pachernegg, Journal für Kardiologie, Nummer 7-8/2007

Darbepoetin alfa bei der Therapie von Chemotherapie-induzierter Anämie. E. Walter. In: Krankenhauspharmazie, 27. Jahrgang, Heft 1, Januar 2006 

Österreichische Guidelines zur gesundheitsökonomischen Evaluation. E. Walter. In: Beilage Ökonomie & Gesundheit zu Recht der Medizin, 2006/1

Österreichische Guidelines zur gesundheits-ökonomischen Evaluation. E. Walter. In: PharmacoEconomics – German Research Articles 2006 4(2)

Theoretische Implikationen zur gesundheitsökonomischen Evaluation mit Ausblick auf Österreich. E. Walter, S. Zehetmayr. In: Wiener Medizinische Wochenschrift 23/24 2006

Guidelines zur gesundheitsökonomischen Evaluation – Konsensuspapier. E. Walter, S. Zehetmayr. In: Wiener Medizinische Wochenschrift 23/24 2006

Dimensionen der Ausgaben für das österreichische Gesundheitswesen 2003. E. Walter. In Wirtschaftspolitische Blätter 4/2005

Cost-Effectiveness of Escitalopram versus Citalopram in the treatment of severe depression in Austria. EM. Hermels, S. Kasper, E. Walter TR. Einerson. In: The Annals of Pharmacotherapy Vol. 38, June 2004

Cost-Effectiveness of Escitalopram: A new SSRI in the first line Treatment of Major depressive disorder in Austria. EM. Hermels, S. Kasper, E. Walter TR. Einerson. In: Current Medical Research and Opinion Vol. 20, No. 6, 2004

Mirtazapin - eine kosteneffektive Behandlung der Depression: eine österreichische Analyse. E. Walter. In: J. NEUROL. NEUROCHIR. PSYCHIATR., 3/2003